While the implementation of the FDA Amendments Act meant changes so significant the agency stopped focusing on meeting review deadlines, the simpler adjustments under 2012’s FDA Safety and Innovation Act should not be as disruptive, Office of New Drugs Director John Jenkins told Elsevier Business Intelligence’s FDA/CMS Summit Dec. 10.
FDASIA’s new review model for NMEs and novel BLAs, which Jenkins calls “the program,” is “a major new addition” to CDER’s review architecture, he said, but “the individual components are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?